Drug Trial Radar · NCT02799095
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Sep 14, 2016
Primary completion
Mar 27, 2023
Study completion Aug 2, 2023
Sponsor
- Lead sponsor
- Mural Oncology, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To better understand the safety and tolerability of ALKS 4230 in humans
Conditions
- Advanced Solid Tumors
Interventions
ALKS 4230Drug
Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
ALKS 4230 + pembrolizumabDrug
IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)Time frame: Cycle 1 Day 1 through Cycle 2 Day 15 (Cycle 1 length = 14 days; Cycle 2 length= 21 days)
- Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)
- Parts A, B, and C: Number of Participants With TEAEs by Severity GradingTime frame: From first dose of study drug until 30 days after last dose (up to 10 months for Part A; up to 41.3 months for Part B; up to 51.5 months for Part C)
- Parts B and C: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: From first dose of study drug up to 40.3 months for Part B and up to 50.5 months for Part C
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
Mural Oncology Investigational Site
Denver, Colorado
Mural Oncology Investigational Site
Port Saint Lucie, Florida
Mural Oncology Investigational Site
Tampa, Florida
Mural Oncology Investigational Site
Lexington, Kentucky
Mural Oncology Investigational Site
Boston, Massachusetts
Mural Oncology Investigational Site
Detroit, Michigan
Mural Oncology Investigational Site
Buffalo, New York
Mural Oncology Investigational Site
New York, New York
Mural Oncology Investigational Site
Cleveland, Ohio
Mural Oncology Investigational Site
Dallas, Texas
Mural Oncology Investigational Site
Fairfax, Virginia
Mural Oncology Investigational Site
Spokane, Washington
Mural Oncology Investgational Site
Albury, New South Wales, Australia
Mural Oncology Investigational Site
Waratah, New South Wales, Australia
Mural Oncology Investigational Site
Brussels, MO, Belgium
Mural Oncology Investigational Site
Kortrijk, West-Vlaanderen, Belgium
Mural Oncology Investigational Site
Edmonton, Alberta, Canada
Mural Oncology Investigational Site
Hamilton, Ontario, Canada
Alkermes Investigational Site
Toronto, Ontario, Canada
Mural Oncology Investigational Site
Montreal, Quebec, Canada
Mural Oncology Investigational Site
Québec, Quebec, Canada
Mural Oncology Investigational Site
Skorzewo, Poznan, Poland
Mural Oncology Investigational Site
Daejeon, South Korea
Mural Oncology Investigational Site
Seoul, South Korea
Mural Oncology Investigational Site
Seoul, South Korea
Mural Oncology Investigational Site
Barcelona, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.